Our continuous monitoring across pipelines, regulatory pathways, and commercial landscapes means we’re not starting research when you ask a question. We’re sharing what we’ve already been tracking.
Our continuous monitoring across pipelines, regulatory pathways, and commercial landscapes means we’re not starting research when you ask a question. We’re sharing what we’ve already been tracking.
Shiv Nayyar is Vice President of Consulting Services at Fuld, bringing more than 10 years of experience in healthcare and life sciences consulting. He specializes in opportunity assessments, customer segmentation, forecasting, benchmarking, and go-to-market strategy. Shiv holds
Some of our analysts have tracked oncology, immunology, or rare diseases for 20+ years. When you ask about emerging competition, we’re not researching—we’re remembering. We know which companies pivoted from failed programs, which executives over-promise timelines, and which therapeutic approaches have been tried before. This institutional memory turns into predictive advantage.
We work with 75+ physicians, clinical researchers, and former regulatory reviewers who assess whether mechanisms will actually work, not just whether they sound innovative. If we tell you a competitor’s trial will face enrollment challenges, it’s because investigators in that indication told us why.
Our NLP tools continuously scan medical literature, trial registries, patents, and conference proceedings to surface threats before they’re obvious. Machine learning models trained on 15 years of approval data forecast regulatory outcomes. AI dashboards track prescription trends and HCP sentiment weeks before syndicated data is available. The AI surfaces signals; our experts interpret what they mean for your strategy.
We alert you to competitive threats before you ask. Most questions get answered in 7-10 days because we’re already tracking the space—you’re paying us to package intelligence we’ve been building, not to start from scratch. This is why we’re fast without being superficial.
Understanding EU regulatory pathways isn’t the same as knowing how German HTA bodies will actually assess your dossier. Our global network of physicians, payers, and patient advocates provides context that never appears in public filings—the kind of insight that changes how you interpret clinical data or forecast commercial potential.
We don’t send 200-slide decks—we send the 15 slides that answer your question, with backup if needed. Every analysis includes confidence levels, alternative interpretations, and explicit assumptions. We evaluate opportunities through the lens of what payers will cover, what physicians will prescribe, and what patients will actually access—because clinical differentiation doesn’t automatically translate to commercial success.
If you have a question, a challenge, or would like to schedule a no-obligation call to discuss your objectives, contact us here.
Get in Touch
